[{"data":1,"prerenderedAt":158},["ShallowReactive",2],{"drug-flibanserin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":36,"contraindications":59,"warnings":69,"renal":79,"monitoring":80,"interactions":81,"review":82,"examples":85,"atc":91,"iran":93,"links":101,"populations":118,"usApproval":153},"flibanserin",1,{"fa":7,"en":8},"فلیبانسرین","Flibanserin","genitourinary-sex-hormones",{"fa":11,"en":12},"آگونیست\u002Fآنتاگونیست سروتونین","Serotonin 1A agonist \u002F 2A antagonist",[14],{"name":15,"market":16},"Addyi","US",[18,7,19,20],"addyi","ادی","ویاگرای زنانه",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-100","tablet","oral","100 mg tablet",{"amount":28,"unit":29,"perUnit":24,"scored":30},100,"mg",false,[16],[33],{"source":34,"section":35},"fda-addyi","3",[37],{"id":38,"disease":38,"label":39,"population":42,"type":46,"unit":29,"dose":47,"refs":48,"notes":51},"hsdd",{"fa":40,"en":41},"کاهش میل جنسی زنان پیش از یائسگی — ۱۰۰ mg شب هنگام خواب","HSDD in premenopausal women — 100 mg at bedtime",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":28,"dosesPerDay":5},[49],{"source":34,"section":50},"2.1",[52],{"text":53,"refs":56},{"fa":54,"en":55},"فقط هنگام خواب (خطر افت فشار و غش). اگر پس از ۸ هفته بهبودی نبود قطع شود.","Bedtime only (risk of hypotension and fainting). Stop if no improvement after 8 weeks.",[57],{"source":34,"section":58},"2",[60],{"id":61,"severity":62,"text":63,"refs":66},"ci","block",{"fa":64,"en":65},"مهارکننده متوسط یا قوی CYP3A4؛ نارسایی کبد؛ حساسیت.","Moderate or strong CYP3A4 inhibitors; hepatic impairment; hypersensitivity.",[67],{"source":34,"section":68},"4",[70],{"text":71,"refs":74},{"fa":72,"en":73},"هشدار جعبه‌ای: افت فشار و غش با الکل؛ دست‌کم ۲ ساعت بعد از ۱ تا ۲ نوشیدنی الکلی مصرف شود یا آن شب حذف شود.","Boxed warning: hypotension and syncope with alcohol; wait at least 2 h after 1–2 drinks or skip that night’s dose.",[75,77],{"source":34,"section":76},"Boxed Warning",{"source":34,"section":78},"5.1",[],[],[],{"status":83,"reviewer":84,"date":84},"unverified",null,[86],{"regimen":38,"formulation":23,"input":87,"expect":90},{"ageYears":88,"weightKg":89},35,60,{"perDose":28,"tabletsPerDoseRounded":5},[92],"G02CX02",{"status":94,"forms":95,"refs":96},"registered",[],[97],{"source":98,"section":99,"url":100},"darooyab-generic","G-5564\u002FFlibanserin","https:\u002F\u002Fwww.darooyab.ir\u002FG-5564\u002FFlibanserin",[102,106,110,113,116],{"kind":103,"url":104,"label":105},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022526","NDA022526",{"kind":107,"url":108,"label":109},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394","FDA Addyi",{"kind":111,"url":112,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa615040.html",{"kind":114,"url":115,"label":92},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=G02CX02",{"kind":117,"url":100,"label":8},"darooyab",{"pregnancy":119,"lactation":128,"pediatric":136,"geriatric":145},{"level":120,"text":121,"quote":124,"refs":125},"caution",{"fa":122,"en":123},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no studies of ADDYI in pregnant women to inform whether there is a drug-associated risk in humans.",[126],{"source":34,"section":127},"8.1",{"level":120,"text":129,"quote":132,"refs":133},{"fa":130,"en":131},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Flibanserin is excreted in rat milk.",[134],{"source":34,"section":135},"8.2",{"level":137,"text":138,"quote":141,"refs":142},"not-established",{"fa":139,"en":140},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","ADDYI is not indicated for use in pediatric patients.",[143],{"source":34,"section":144},"8.4",{"level":120,"text":146,"quote":149,"refs":150},{"fa":147,"en":148},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","ADDYI is not indicated for the treatment of HSDD in geriatric patients [see Warnings and Precautions (5.1 . 5.2 , and 5.4 )] .",[151],{"source":34,"section":152},"8.5",{"kind":154,"refs":155,"id":105},"NDA",[156],{"source":34,"section":157},"SPL approval \u002F marketing category",1792091059167]